ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.
Immunome Inc

Immunome Inc (IMNM)

20.58
-0.44
(-2.09%)
Closed April 13 4:00PM
20.58
0.00
(0.00%)
After Hours: 4:00PM

Unlock more advanced trading tools

Join ADVFN today

Key stats and details

Current Price
20.58
Bid
20.14
Ask
21.16
Volume
305,366
20.31 Day's Range 21.03
4.44 52 Week Range 30.958
Market Cap
Previous Close
21.02
Open
20.55
Last Trade
62
@
20.31
Last Trade Time
Financial Volume
$ 6,290,151
VWAP
20.5987
Average Volume (3m)
750,778
Shares Outstanding
42,729,847
Dividend Yield
-
PE Ratio
-23.47
Earnings Per Share (EPS)
-0.88
Revenue
-
Net Profit
-37.52M

About Immunome Inc

Immunome Inc is a biopharmaceutical company. It is engaged in utilizing proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The company's primary focus areas are oncology and infectious... Immunome Inc is a biopharmaceutical company. It is engaged in utilizing proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The company's primary focus areas are oncology and infectious disease, including COVID-19. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Headquarters
Wilmington, Delaware, USA
Founded
1970
Immunome Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker IMNM. The last closing price for Immunome was $21.02. Over the last year, Immunome shares have traded in a share price range of $ 4.44 to $ 30.958.

Immunome currently has 42,729,847 shares outstanding. The market capitalization of Immunome is $880.66 million. Immunome has a price to earnings ratio (PE ratio) of -23.47.

IMNM Latest News

Immunome to Present Preclinical Data for IM-3050, Its Lead Radioligand Therapy Candidate, at 2024 American Association for Cancer Research (AACR) Annual Meeting

Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that it will present preclinical data for...

Immunome Reports Full Year 2023 Financial Results and Provides Update on Recently Acquired Assets

Topline data for Phase 3 RINGSIDE trial of AL102 expected in first quarter of 2025 IM-1021 and IM-3050 IND filings expected in first quarter of 2025 Current cash expected to fund activities into...

Immunome Completes Acquisition of AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala

Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the successful completion of its purchase...

Immunome to Participate in the Leerink Partners Global Biopharma Conference

Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that Clay Siegall, Ph.D., President and...

Immunome to Participate in the TD Cowen 44th Annual Healthcare Conference

Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that Clay Siegall, PhD, President and CEO...

Immunome Recognizes Ayala Pharmaceuticals’ Announced Completion of Enrollment in Phase 3 RINGSIDE Study Evaluating AL102 in Desmoid Tumors

– Immunome entered into a definitive asset purchase agreement with Ayala to acquire AL102 earlier this month – Immunome, Inc. (Nasdaq: IMNM), a biotechnology company dedicated to developing...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.412.0327218641520.1721.2519.5850694920.39442015CS
4-1.57-7.0880361173822.1526.719.5860802122.60376897CS
127.3255.203619909513.2630.95812.78575077822.51320313CS
2612.68160.5063291147.930.9586.9345849819.50192188CS
5215.26286.8421052635.3230.9584.4430093716.58197063CS
156-9.42-31.43032.44762.0917983315.8384754CS
2604.9231.417624521115.6663.782.0917789817.86542964CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
PXMDPaxMedica Inc
$ 0.8385
(103.59%)
114.3M
MNDRMobile health Network Solutions
$ 14.87
(45.78%)
10.66M
CNXAConnexa Sports Technologies Inc
$ 1.50
(38.89%)
16.88M
PRZOParaZero Technologies Ltd
$ 1.08
(38.46%)
12.94M
BENFBeneficient
$ 0.09542
(38.09%)
122.81M
MOTSMotus GI Holdings Inc
$ 0.2631
(-37.76%)
1.79M
CISSC3is Inc
$ 1.865
(-35.24%)
5.7M
LXEHLixiang Education Holding Company Ltd
$ 0.4325
(-33.46%)
3.12M
GVHGlobavend Holdings Ltd
$ 1.20
(-29.82%)
227.4k
SLNHSoluna Holdings Inc
$ 1.59
(-28.05%)
423.89k
SQQQProShares UltraPro Short QQQ
$ 10.89
(4.71%)
176.08M
NKLANikola Corporation
$ 0.7014
(-2.18%)
134.38M
BENFBeneficient
$ 0.09542
(38.09%)
122.81M
PXMDPaxMedica Inc
$ 0.8385
(103.59%)
114.3M
AAPLApple Inc
$ 176.55
(0.86%)
101.67M

IMNM Discussion

View Posts
Monksdream Monksdream 3 weeks ago
IMNM 10Q due 3/22
👍️0
Monksdream Monksdream 1 month ago
IMNM new 52 week hi
👍️0
Monksdream Monksdream 3 months ago
IMNM new 52 week high
👍️0
OncoJock OncoJock 4 months ago
Agree.

Wish there were most posts on this board.

Wondering who might be the next big customer to sign a major discovery and commercialization contract with IMNM, after AbbVie?

Also wondering if IMNM is doing any discovery/testing/research related to bispecific antibodies, as opposed to antibody-drug conjugates. Bispecifics are HOT HOT HOT in lymphoma and myeloma.

-- OJ
👍️0
OncoJock OncoJock 4 months ago
agree
👍️0
Laster Laster 6 months ago
Hopefully the vote passed.
I think this biotech combined company can be a huge success.
Siegall has proven he can build a biotech company.
This will be fun to watch.
👍️ 1
Laster Laster 7 months ago
I believe merger news tomorrow along with huge financing.
Clay B. Siegall To become chairman and CEO of combined company.
He founded Seagen which just sold for $40 billion to Pfizer.
Their innovative technology from Professor Philip S. Low (Purdue University).
Look at Professor Low accomplishments. Unreal.
Watching closely because this might become a huge biotech company.
👍️ 1
wiwineguy wiwineguy 9 months ago
Ha, sold in fall of 21 for $25.
👍️0
makinezmoney makinezmoney 9 months ago
$IMNM: Now 10.40 !!!!!!!!!!!

Booooooooooooyakashaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa


Immunome and Morphimmune Announce Definitive Merger Agreement and Simultaneous Private Placement Investment of $125 Million to Develop Targeted Cancer Therapies



GO $IMNM
👍️0
makinezmoney makinezmoney 9 months ago
$IMNM: Boooommmmmmmmmmmmmmm.......now $8.50


Offfffffffffff she goes.

Nice boomer



GO $IMNM
👍️0
Awl416 Awl416 9 months ago
Immunome and Morphimmune Announce Definitive Merger Agreement and Simultaneous Private Placement Investment of $125 Million to Develop Targeted Cancer Therapies
👍️ 1
wiwineguy wiwineguy 3 years ago
you don't know crap majorbankz. you keep saying i "heard" this, and I "heard" that. can you be any more vague. stfu
👍️0
Harbor6460 Harbor6460 3 years ago
They cannot dilute on the bid. Only the ask
👍️0
Pedro2004 Pedro2004 3 years ago
Pulled down to under $20.00
👍️0
Pedro2004 Pedro2004 3 years ago
They pulled this down to under $21.00

I'm back-in at $21.00
👍️0
Major_Bankz Major_Bankz 3 years ago
$22.50 U worry too much, should be $25+ this afternoon IMO
👍️0
Pedro2004 Pedro2004 3 years ago
I thought this was going to break today. But it' just jumped over $22 -- let's see if that holds.
👍️0
Pedro2004 Pedro2004 3 years ago
This run could have broke $30 today. But the company killed-it.
👍️0
Major_Bankz Major_Bankz 3 years ago
yep, shorties portfolio will get destroyed here.
👍️0
Pedro2004 Pedro2004 3 years ago
The dilution is going to kill this run.
👍️0
Pedro2004 Pedro2004 3 years ago
Looks like the company is dumping shares on the bid.
👍️0
Major_Bankz Major_Bankz 3 years ago
I don't think PFE and MRNA can claim the same effectiveness for DELTA, plus time to buy is during development not after just like when MRNA was at $20. IMO
👍️0
Major_Bankz Major_Bankz 3 years ago
Delta is a BIG problem, IMNM may catch up to PFE and MRNA. IMO
👍️0
Major_Bankz Major_Bankz 3 years ago
Immunome was awarded a $17.6 million technology award from the U.S. Department of Defense's Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND), in collaboration with the Defense Health Agency, to support Immunome’s COVID program.

Given the near-term potential for a resurgence of COVID-19 infections driven by emerging variants, Immunome intends to explore opportunities to expedite the development of this potential therapeutic. The Company plans to submit an IND application with the U.S. Food and Drug Administration (FDA) this quarter.
👍️0
Major_Bankz Major_Bankz 3 years ago
IMNM $21 Immunome Antibody Cocktail (IMM-BCP-01) Neutralizes the SARS-CoV-2 Delta Variant in Pre-clinical Testing
👍️0

Your Recent History

Delayed Upgrade Clock